EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Checkpoint inhibitors, obinutuzumab plus PET ‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘ FLUORO’ study

Arina Martynchyk iD, Geoffrey Chong iD, Richard Khor, Denise Lee iD, Sze Ting Lee, Andrew M Scott, Anneke C Grobler, Belinda A Campbell, Thanuja Thachil, Kate Manos iD, Genevieve Douglas iD, Alexandra Romano und 4 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70468 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Arina Martynchyk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Haematology, Austin Health, Heidelberg, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Lymphoma, Follicular, Positron-Emission Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Products Pty Limited (Australia), Victorian Comprehensive Cancer Centre Alliance, Investigator Initiated trials programs, Trial Assistance Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)‐adapted ultra‐low dose radiotherapy (RT; 4Gy) to all PET‐avid sites after cycle 2, followed by 2 years of obinutuzumab maintenance. Sixteen eligible patients were enrolled (15 evaluable for response) to our Phase II trial (NCT04962126). Median age was 53 years with 94% intermediate/high Follicular Lymphoma International Prognostic Index (FLIPI) score. The primary end‐point of complete response (CR) was achieved in 93% (95% confidence interval [CI]: 70%–99%) with objective response rate (ORR) of 100% (95% CI: 75%–100%). With 41‐month median follow‐up, 3‐year progression‐free survival (PFS) was 80% (95% CI: 55–93) and OS was 100% (95% CI: 79.6–100). Grade 3–4 adverse events occurred in 31% of patients (2 immune‐related). Baseline PET radiomics and immune transcriptomics demonstrated profiles suggesting promise as predictive markers of immunotherapy response, consistent with our prior findings. The novel multimodality combination of obinutuzumab, atezolizumab and ultra‐low dose nodal RT in treatment‐naïve FL has promising efficacy and safety, offering a potential novel chemo‐free option. Further studies using low‐cost RT to augment immunotherapy are warranted. This trial was registered in clinicaltrials.gov , registration number: NCT04962126.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsLymphoma, FollicularPositron-Emission TomographyAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Stichwörter der Autor:innen

clinical trialfollicular lymphomaimmunotherapyradiotherapy

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorsobinutuzumab

Autor:innen und Institutionen

  • Clinical Haematology, Austin Health, Heidelberg, Australia.
  • Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
  • Grampians Health, Ballarat, Australia.
  • Radiation Oncology, Austin Health, Melbourne, Australia.
  • Department of Medical Imaging and Radiation Sciences, Monash University, Melbourne, Australia.
  • Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.

ORCID-Profile: Arina Martynchyk, Geoffrey Chong, Denise Lee, Kate Manos, Genevieve Douglas, Eliza A Hawkes

Förderung

  • Roche Products Pty Limited (Australia)
  • Victorian Comprehensive Cancer Centre Alliance, Investigator Initiated trials programs, Trial Assistance Scheme

Zitieren

APA

Martynchyk, A., Chong, G., Khor, R., Lee, D., Lee, S. T., Scott, A. M., Grobler, A. C., Campbell, B. A., Thachil, T., Manos, K., Douglas, G., Romano, A., Palmer, J. B., Burgess, M., Keane, C., & Hawkes, E. A. (2026). Checkpoint inhibitors, obinutuzumab plus PET ‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘ FLUORO’ study. British Journal of Haematology. https://doi.org/10.1111/bjh.70468

Vancouver

Martynchyk A, Chong G, Khor R, Lee D, Lee ST, Scott AM, et al. Checkpoint inhibitors, obinutuzumab plus PET ‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘ FLUORO’ study. British Journal of Haematology. 2026. doi:10.1111/bjh.70468

BibTeX
@article{Martynchyk2026,
  author = {Martynchyk, Arina and Chong, Geoffrey and Khor, Richard and Lee, Denise and Lee, Sze Ting and Scott, Andrew M and Grobler, Anneke C and Campbell, Belinda A and Thachil, Thanuja and Manos, Kate and Douglas, Genevieve and Romano, Alexandra and Palmer, Jodie B and Burgess, Melinda and Keane, Colm and Hawkes, Eliza A},
  title = {Checkpoint inhibitors, obinutuzumab plus PET ‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘ FLUORO’ study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70468}
}
Kostenlos starten →